

# Mitigation Strategies for Nitrosamine Drug Substance Related Impurities: Quality and Bioequivalence Considerations for Generics

## SESSION 2: Safety & Risk Assessment of NDSRIs for Human Health

### *Presenters:*

**Robert H. Heflich, PhD**

**David Ponting, MA, MSci, PhD**

**Naomi Kruhlak, PhD**

**Andrew Teasdale, BSc (Hons), PhD**

**Raphael Nudelman, PhD, ERT**

Director, DGMT, NCTR, FDA, FDA Acting

Principal Scientist, Lhasa Limited

Scientific Lead, DARS, OCP, OTS, CDER, FDA

Senior Principal Scientist, AstraZeneca

Senior Director Impurity Expert, Teva

### *Moderator:*

**Robert T. Dorsam, PhD**

Director, DPTR, OSCE, OGD, CDER, FDA

### *Panelists:*

**Andrew Teasdale, BSc (Hons), PhD**

Senior Principal Scientist, AstraZeneca

**David Ponting, MA, MSci, PhD**

Principal Scientist, Lhasa Limited

**Naomi Kruhlak, PhD**

Scientific Lead, DARS, OCP, OTS, CDER, FDA

**Raphael Nudelman, PhD, ERT**

Senior Director Impurity Expert, Teva

**Robert H. Heflich, PhD**

Director, DGMT, NCTR, FDA

**Sruthi King, PhD**

Deputy Director, DPTR, OSCE, OGD, CDER, FDA